| Stephanie Lynn Woods, | |
|
1000 1st St N, Alabaster, AL 35007-8703 | |
| (205) 620-7059 | |
| Not Available |
| Full Name | Stephanie Lynn Woods |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Neonatal, Critical Care |
| Location | 1000 1st St N, Alabaster, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043558356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LN0005X | Nurse Practitioner - Neonatal, Critical Care | 1-040477 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Lynn Woods, 1000 1st St N, Alabaster, AL 35007-8703 Ph: () - | Stephanie Lynn Woods, 1000 1st St N, Alabaster, AL 35007-8703 Ph: (205) 620-7059 |
News Archive
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.
Post-traumatic stress disorder affects nearly 8 million adults in any given year, federal statistics show. Fortunately, clinical research has identified certain psychological interventions that effectively ameliorate the symptoms of PTSD. But most people struggling with PTSD don't receive those treatments, according to a new report published in Psychological Science in the Public Interest.
After the age of nine months, the development of the infant gut microbiota is driven by the transition to family foods, not maternal obesity, according to results from a new study. The study was published online this week in mSphere, an open-access journal of the American Society for Microbiology.
Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving cell growth and division, but also by turning off protective tumor suppressor genes, which normally limit uncontrolled cell growth and cause damaged cells to self-destruct.
Roche has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) to market Tamiflu (oseltamivir phosphate) capsules in pediatric doses of 30 mg and 45 mg.
› Verified 1 days ago
Jenifer Justice, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 145 Sundance, Alabaster, AL 35007 Phone: 662-640-8804 | |
Mrs. Amanda T Cabaniss, RN, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1024 1st St N, Central Alabama Oncology, Llc, Alabaster, AL 35007 Phone: 205-664-4051 Fax: 205-664-4054 | |
Brody Weldon, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7004 | |
Mr. Ricardo Paitz, ACNPC-AG Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8100 | |
Jennifer Gafnea, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 300 1st St N Ste C, Alabaster, AL 35007 Phone: 205-381-2381 | |
William Alexander Woodard, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 1st Street North Ste. C, Alabaster, AL 35007 Phone: 205-663-5990 |